Entrectinib in patients with ROS1 fusion-positive (ROS1-fp) NSCLC: updated efficacy and safety analysis
Authors
Fan, Y.Drilon, A.
Chiu, C. H.
Bowles, D. W.
Loong, H. H. F.
Siena, S.
Goto, K.
Krzakowski, M.
Ahn, M. J.
Murakami, H.
Dziadziuszko, R.
Zeuner, H.
Pitcher, B.
Cheick, D.
Krebs, Matthew G
Affiliation
Zhejiang Cancer Hospital, HangzhouIssue Date
2022
Metadata
Show full item recordCitation
Fan Y, Drilon A, Chiu CH, Bowles DW, Loong HHF, Siena S, et al. Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis. Journal of Thoracic Oncology. 2022 Sep;17(9):S89-S90. PubMed PMID: WOS:000858678100139.Journal
Journal of Thoracic OncologyDOI
10.1016/j.jtho.2022.07.150Additional Links
https://dx.doi.org/10.1016/j.jtho.2022.07.150Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jtho.2022.07.150